PEOPLE - World Health Organization makes appointment:
This article was originally published in Clinica
Executive Summary
David Byrne is to become a special envoy for the World Health Organization (WHO) at the end of his tenure as European Commissioner for health and consumer protection. (That was due to be October 31, but Commission President-Designate Jose-Manuel Barroso decided on October 27 not to submit the new Commission for Parliament's approval, due to objections to the nomination of one Commission (human rights). A new Commission will now not be submitted for some weeks.) Mr Byrne's new role will be to facilitate the process of negotiation of a revised draft of regulations in view of the coming meeting of officials from WHO's 192 member states on November 1-12. The final draft will be presented to the world health assembly in May 2005.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.